Menu Search
Equities

Immunotech Biopharm Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6978:HKG.HS

Immunotech Biopharm Ltd

Actions
  • Price (HKD)2.59
  • Today's Change0.00 / 0.00%
  • Shares traded40.00k
  • 1 Year change+6.30%
  • Beta-0.1053
Data delayed at least 15 minutes, as of Feb 13 2026 03:53 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Immunotech Biopharm Ltd is an investment holding company primarily engaged in the research and development, manufacturing and commercialisation of immune cell products for treatments of cancers. The Company's non-genetically modified cell product pipeline includes Expanded Activated Lymphocytes (EAL) and 6B11-OCIK Injection. The Company's chimeric antigen receptor T (CAR-T) cell product pipeline includes CAR-T-19 Injection, Denocabtagene Ciloleucel Injection and aT19 Injection. The Company's T cell receptor engineered T cell therapy (TCR-T) cell product pipeline includes YT003, YT008 and YT007. The Company mainly conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-253.13m
  • Incorporated2018
  • Employees173.00
  • Location
    Immunotech Biopharm Ltd8th Floor, Building 1Guosheng Science and Technology ParkNo.1 Kangding Street, Economic and TechnBeijing ChinaCHN
  • Websitehttps://www.eaal.net/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.